Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview.
Hyperhomocysteinaemia has been regarded as a new modifiable risk factor for atherosclerosis and vascular disease. Homocysteine is a branch-point intermediate of methionine metabolism, which can be further metabolised via two alternative pathways: degraded irreversibly through the transsulphuration pathway or remethylated to methionine by the remethylation pathway. Both pathways are B-vitamin-dependent. Plasma homocysteine concentrations are determined by nongenetic and genetic factors. The metabolism of homocysteine, the role of B vitamins and the contribution of nongenetic and genetic determinants of homocysteine concentrations are reviewed. The mechanisms whereby homocysteine causes endothelial damage and vascular disease are not fully understood. Recently, a link has been postulated between homocysteine, or its intermediates, and an alterated DNA methylation pattern. The involvement of epigenetic mechanisms in the context of homocysteine and atherosclerosis, due to inhibition of transmethylation reactions, is briefly overviewed.
Castro
R
R
Centro de Patogénese Molecular, Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, Lisbon 1649-003, Portugal.
Rivera
I
I
Blom
H J
HJ
Jakobs
C
C
Tavares de Almeida
I
I
D000818:Animals; D019175:DNA Methylation; D005260:Female; D006710:Homocysteine / Q000378:metabolism*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D008297:Male; D008954:Models, Biological; D014652:Vascular Diseases / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D014803:Vitamin B Complex / Q000378:metabolism
D006710:Homocysteine; D014803:Vitamin B Complex